| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_44c713790ce00813da2e6c6d57a29456 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056 |
| filingDate |
2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32653d51d1fc26bf65980e879e3c2f6f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae5b23ddf4f69c267ef866bb79fbac94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_975d2ce0a0c885fcc87b9a1913c8d1b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4277ea731ffa276aab05a5ce7fdf56b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66cfdffdd658897a211f2eab741e8cee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e415c7e93dd9e543008efd9f52e4e2e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2583e889b69b4c3577db49c66d854163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b83314e58a5b918895ee92241be1372 |
| publicationDate |
2009-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2009107947-A |
| titleOfInvention |
Antidiabetic agent comprising pyrazolyl 5-thioglucoside compound as an active ingredient |
| abstract |
The present invention provides a novel compound that controls IGT (abnormal glucose tolerance) by selectively inhibiting SGLT1 activity and suppressing glucose absorption from the gastrointestinal tract. The following general formula (I) A prophylactic or therapeutic agent for diabetes comprising the pyrazolyl-5-thioglucoside compound represented by the formula (1) or a pharmaceutically acceptable salt thereof or a hydrate thereof as an active ingredient. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011039338-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012023600-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9161945-B2 |
| priorityDate |
2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |